Description: Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Home Page: www.anthera.com
The Pennzoil Building
Houston,
TX
77002
United States
Phone:
410 350 1839
Officers
| Name | Title |
|---|---|
| Mr. Paul F. Truex M.B.A., MBA | Exec. Chairman |
| Mr. John Craig Thompson | CEO & Director |
| Ms. May Liu | Sr. VP of Fin. & Admin. and Principal Accounting Officer |
| Dr. Paul Adams Ph.D. | Sr. VP of Global Regulatory Affairs and Compliance |
| Joshua Caldwell | Chief Liquidating Officer |
| Mr. Bradley A. Bugdanowitz Esq. | Sec. |
| Ms. Klara A. Dickinson-Eason | Advisor |
| Dr. Charles V. Olson D.Sc. | Advisor |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1131 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2010-03-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |